Given that the CIN subtype is induced by recurrent amplifications of genes encoding RTKs, such as EGFR, fibroblast growth factor receptor 2 (FGFR2), human epidermal growth factor receptor 2 (HER2), and MET and cell-cycle mediators, several researchers have suggested that CINaGC may be sensitive to RTK-targeted agents or DNA damaging drugs. The gene discussed is ERBB2; the disease is cervical squamous intraepithelial neoplasia.